For any urgent medical matters, please go to the urgent care or emergency room.
Please schedule online, using the QR code. Only Tuesday or Thursday shot appts available. CONSIDER AT-HOME SUBLINGUAL ALLERGEN IMMUNOTHERAPY DROPS-ASK OUR STAFF ABOUT IT. IT’S SAFE AND CONVENIENT.
If you are due for a refill please schedule a virtual appointment followed by allergy skin testing so we can make changes as needed to your formulation prior to mixing your refill.
Springtime both allergy and asthma patient’s may experience increase in their symptoms. Be sure to check in with us for a quick virtual visit to make sure you are on the right treatment regimen.
Dupixent (Dupilumab), is a monoclonal antibody designed for the treatment of allergic diseases such as eczema and asthma by blockage of IL-4Rα, dupilumab modulates signaling of both the interleukin 4 and interleukin 13 pathways, which are allergic pathways.
Indicated for 6 monhts and older for eczema and 6 years and older for asthma, contact our office if you are interested in a non-steroidal treatment for your child’s moderate to severe asthma or eczema.
For patients with dust mite allergy who are looking to lessen their dust mite allergy symptoms without medication should consider Odactra, a sublingual tablet of concentrated dustmite protein to help teach your body’s immune system to tolerate dust mites. The first dose is taken in the office and then at home! It’s covered by insurance plans. See if you are a candidate, call to make an appointment (703) 558-6040.
For infants at high risk, meaning they have eczema, food allergy, sibling with food allergy (especially peanut) or parents with allergies, the LEAP study showed that early introduction of peanut prevented a peanut allergy in most infants.
We offer an evaluation for these high-risk patients and if negative, then we can start patients safely on this preventative therapy and if borderline peanut reaction on allergy skin test, can offer a peanut challenge in the office.
Proper evaluation, dosing and frequency is important to make this therapy successful.
A positive allergy test alone does not determine a patient’s allergy status. The size of skin test and/or level of specific IgE, the patient’s age, specific food and history all go into allowing a board-certified allergist to use their training to determine if a patient has a food allergy. If needed, an oral challenge may be also utilized to help determine if a patient is truly allergic to a food an not unnecessarily avoiding a food. If your doctor does not offer an oral challenge as a possible option to determine your allergy status then they should not be testing you for allergies. Be educated, a fellowship trained board-certified allergist will be able to provide you the best possible allergy care.
Research results show both oral and sublingual therapy is helpful.
Another step in the right direction to bring such therapies to our patients soon.
FDA Grants Priority Review to Xolair (omalizumab) for Children and Adults With Food Allergies Based on Positive National Institutes of Health Phase III Study Results
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
For infants under the age of 12months, if they are at high risk (+family history of peanut allergy; eczema, allergies), we are offering early introduction protocol in order to prevent them from developing a peanut allergy.
Based on the LEAP Study, regular feeding of peanut protein to children at high risk can significantly reduce the development of peanut allergy.
Make an appt for your at risk infant to be evaluated for a peanut allergy, prior to starting the introduction.